Glycan Therapeutics

2:00 PM - 2:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 104A
Glycan Therapeutics is a pioneer in design and synthesis of structurally homogeneous oligosaccharides, heparan sulfate (HS) and chondroitin sulfate (CS). Using our proprietary enzyme-based platform technology we developed three lead molecules in various stages of development for anticoagulant and anti-inflammatory indications. Glycan Therapeutics has reached significant milestones to replace the supply chain constrained animal derived heparin, with a synthetic molecule amenable to a fully controlled manufacturing process. Glycan provides a one stop-shop for design, synthesis and analysis of HS and CS using microarray and LC-MS tools. Our research support services have customers from industry and academia all over the world. With distributors in Europe, US and Asia Glycan's research and reagents attracts customers from big Pharma and academic institutions.
Company Type:
Privately Funded Company
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
Dekaparin for anticoagulant and antiinflammatory indications
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chief Operating Officer
Glycan Therapeutics